2026 Program

At BIO 2026, where science meets real-world impact, you can access more than 135 sessions across 18 focus areas with discussions from leading biotechnology companies, investors, service providers, government officials, regulators and patient advocates.

Accelerate your career growth by adding a Professional Development Course to your BIO 2026 registration. Learn more.

Loading
1:00 PM (PT)
  1. Company Presentations
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
1:45 PM (PT)
  1. This session brings together leaders from pharma, AI technology, life sciences platforms, CROs, and specialized biotech AI to cut through the noise and examine how artificial intelligence is deliverin ...
    Breakout Session 28ABCDE
  2. Our industry has faced a variety of geopolitical and economic issues that inject uncertainty into deal-making. We must now navigate an unprecedented wave of legislation, executive orders, and policies ...
    Breakout Session 25ABC
  3. The healthcare ecosystem is experiencing an unprecedented transformation fueled by scientific, technological, geopolitical, economic, and demographic changes. Whilst breakthrough innovations are shapi ...
    Breakout Session 29C
  4. Real world data (RWD) are increasingly relied upon to inform drug policy decisions at both the state and federal levels. For example, state Prescription Drug Affordability Boards (PDABs) are using all ...
    Breakout Session 26AB
2:00 PM (PT)
  1. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage (Booth #3035)
3:00 PM (PT)
  1. The financing and partnering environment for biotech has shifted significantly in recent years. Investors and partners have increasingly prioritized tangible, de-risked assets that offer compelling th ...
    Breakout Session 25ABC
  2. For the first time in history, a patient has survived more than eight months following a gene-edited pig organ transplant, marking a pivotal moment as xenotransplantation moves from experimental promi ...
    Breakout Session 24BC
  3. Biomarker legislation is reshaping insurance and diagnostics policy across many US states, with more than 20 currently mandating coverage for biomarker testing under certain conditions. However, trans ...
    Breakout Session 26AB
4:15 PM (PT)
  1. This session will explore how quantum computing is poised to redefine the frontiers of drug discovery by solving complex molecular and optimization problems that exceed the limits of classical computi ...
    Breakout Session 28ABCDE
  2. Clinical trials for large-population diseases face persistent challenges and remain the most complex and resource-intensive steps in drug development. Patient recruitment often lags, administrative bo ...
    Breakout Session 29AB
  3. This session will feature a Fireside Chat between the former CEO of Capstan Therapeutics, as they share firsthand experience leading Capstan through one of the marquee M&A deals of 2025, a $2B+ acquis ...
    Breakout Session 30DE
  4. The China-US relationship will have a huge role in shaping the future of global biotech. Yet, this relationship is increasingly defined by both interdependence and tension — with science, supply chain ...
    Breakout Session 29C
  5. There’s no question that drug development is a risky endeavor with scientific, clinical, and commercial risk. Patients and society value advances in science that help people get well, stay healthy, an ...
    Breakout Session 26AB
9:00 AM (PT)
10:00 AM (PT)
  1. BioProcess International Theatre BioProcess Theatre
  2. BioProcess Session BioProcess Theatre
10:15 AM (PT)
  1. • Contracting and Pricing • Demand Forecasting • Gross-to-Net • Pre-/Post- Deal Analysis • Accruals Management • Revenue Management
    BioProcess Session BioProcess Theatre
10:30 AM (PT)
  1. Company Presentations
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
11:00 AM (PT)
  1. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage - Booth 3035
  2. This session will explore the critical journey of translating a scientific concept into a viable CNS therapeutic. Industry leaders will discuss the primary challenges and emerging solutions in neurosc ...
    Breakout Session 24BC
  3. As major patent expirations loom, pricing pressures intensify and R&D productivity comes under strain, large pharmaceutical companies are accelerating dealmaking to fill therapeutic and clinical-stage ...
    Breakout Session 30ABC
  4. Healthcare providers are often faced with the same set of challenges when diagnosing women with Alzheimer’s – debunking the stigma that has shaped the Alzheimer’s narrative for women and their familie ...
    Breakout Session 31C
11:45 AM (PT)
  1. BioProcess Session BioProcess Theatre
12:00 PM (PT)
  1. CDMO Capacity and Client Partnership Panel • How do you ensure your capacity planning aligns with actual client requirements rather than assumptions? • How do you balance multiple clients competing fo ...
    BioProcess Session BioProcess Theatre
12:15 PM (PT)
  1. Super Session
    The biopharma industry has reached a critical inflection point. As it enters new scientific frontiers, it is simultaneously faced with increased budgetary pressures, looming patent cliffs, and—in the ...
    Super Session 28ABCDE
    Sponsored by:
    Upload Image
1:00 PM (PT)
  1. BioProcess Session BioProcess Theatre
1:45 PM (PT)
  1. AI is redefining what’s possible across industries, and nowhere is the opportunity greater than in life sciences. But unlocking its full power requires more than algorithms — it demands bold new ways ...
    Breakout Session 31AB
  2. Macroeconomic challenges that have hindered biotech IPO activity are subsiding and capital markets are expected to improve later in 2026, especially for early-stage biotech companies. Increased M&A ac ...
    Breakout Session 25ABC
  3. This data-driven session from BIO and its market intelligence partner, Norstella, will dive into the state of play for emerging biotech companies. From venture capital and public financing, deal-makin ...
    Breakout Session 29AB
  4. This session will explore how pharma/biotech companies achieve pipeline diversity through portfolio strategy, strategic collaborations, and scientific rigor. The conversation will examine the processe ...
    Breakout Session 30ABC
  5. Rare diseases collectively affect more than 300 million people worldwide, yet fewer than 5% have an approved treatment. As cell and gene therapies (CGTs) progress from scientific aspiration to commerc ...
    Breakout Session 32AB
  6. Nearly a year ago, the One Big Beautiful Bill became law and states immediately felt the implications of its sweeping health care provisions. This session will provide a cross-stakeholder view on how ...
    Breakout Session 30DE
    Sponsored by:
    Upload Image
2:40 PM (PT)
  1. BioProcess International Theatre BioProcess Theatre
3:00 PM (PT)
  1. AI is becoming ubiquitous in biopharma, but no company can unlock its full potential alone. As the industry shifts from "tell me" to "show me," the pressure is on to move beyond the hype and use AI to ...
    Breakout Session 30DE
    Sponsored by:
    Sponsored by Genentech
  2. AI-enabled discovery and multimodal, human-centric datasets are reshaping how biopharma and digital health companies differentiate, partner, and scale. Rather than focusing on capital trends, this ses ...
    Breakout Session 31AB
  3. Women’s health is now a dynamic arena for innovation, data science, and strategic capital deployment. This session brings together leading investors to discuss where smart capital is flowing and how s ...
    Breakout Session 25ABC
  4. Kickstart your journey in biotechnology by exploring the industry’s vast landscape and discovering where your skills and interests can make an impact. Experts will provide an overview of biotech acros ...
    Breakout Session 29AB
3:55 PM (PT)
  1. What manufacturing innovations have delivered the most significant cost reductions while maintaining product quality in your biologics operations? How are you balancing the capital investment required ...
    BioProcess Session BioProcess Theatre
4:15 PM (PT)
  1. For years, therapeutic development for Alzheimer’s and other neurodegenerative diseases has focused on the pathologies within the brain such as, in the case of Alzheimer’s, amyloid plaques and tau tan ...
    Breakout Session 24BC
  2. Since the first drugs were selected for “negotiation,” the Inflation Reduction Act (IRA) has been the target of litigation. Two strains of litigation emerged, with one focusing on the constitutionalit ...
    Breakout Session 23BC
  3. The metabolic disease treatment landscape is transforming rapidly. While GLP-1 receptor agonists have demonstrated remarkable efficacy, addressing the full scope of metabolic dysfunction requires ther ...
    Breakout Session 32AB
  4. We are living in a golden age of biopharmaceutical innovation. Yet, too often, patients face barriers between them and the appropriate treatment they need across various cost-shifting programs. Payers ...
    Breakout Session 29C
9:30 AM (PT)
10:30 AM (PT)
  1. Company Presentations
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
11:00 AM (PT)
  1. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage - Booth 3035
  2. As diagnostics and precision medicine continue to advance, companies developing novel diagnostic technologies, analytical tools, and data-enabled testing solutions are reshaping how disease is detecte ...
    Breakout Session 26AB
  3. This session is designed to provide students with the guidance and connections needed to enter the world of biotechnology after receiving their degree. Panelists will share their personal career journ ...
    Breakout Session 29AB
1:40 PM (PT)
1:45 PM (PT)
  1. Although artificial intelligence (AI) has existed for decades, recent advances in computational power, data availability, and machine learning models have significantly accelerated its development and ...
    Breakout Session 30DE
  2. For centuries, nature, and particularly the innate immune system, has encoded powerful mechanisms for disease control and repair. Today, artificial intelligence (AI) is reshaping drug discovery by rev ...
    Breakout Session 31AB
  3. In recent years, a confluence of global economic, market, and policy shifts have led to the abandonment of more than 1,000 promising treatments in development for rare diseases - many of which deliver ...
    Breakout Session 25ABC
  4. This session will explore ARPA-H’s unique SBIR/STTR funding opportunities and the distinctive commercialization support designed to propel breakthrough companies forward. Attendees will hear firsthand ...
    Breakout Session 30ABC
  5. Both Secretary Kennedy and Commissioner Makary have signaled that there will be a new era of “radical transparency” at the Food and Drug Administration (FDA). Regulatory transparency is generally desi ...
    Breakout Session 29C
  6. Oncology continues to be the leading therapeutic area across the biopharma industry by almost all measures, including global drug sales, number of pipeline programs, venture capital dollar deployment, ...
    Breakout Session 24BC
2:30 PM (PT)
  1. As biopharmaceutical pipelines grow increasingly diverse — encompassing monoclonal antibodies, recombinant proteins, gene therapies, cell therapies, and other novel modalities — the pressure to stream ...
    BioProcess Session BioProcess Theatre
3:00 PM (PT)
  1. This panel discussion addresses a critical paradox in biotechnology investment - while female-founded biotech’s demonstrate superior returns, they receive less than 3% of venture funding. This session ...
    Breakout Session 30ABC
4:15 PM (PT)
  1. Death of expertise in the dawn of AI has been vastly overreported with no sign of its ability to displace creative and disciplined drug discovery teams. Citing Bernstein Research, the Financial Times ...
    Breakout Session 30DE
  2. Back by popular demand, this high-impact session returns to BIO and will guide health and science executives through a proprietary framework developed by LaVoieHealthScience: The LHS Fifteen-Slide Pre ...
    Breakout Session 30ABC
  3. The advances in technology over the past decade have yielded a broad range of biologics for cancer, each with unique attributes. This is great news for patients to have so many tools in the toolkit, b ...
    Breakout Session 24BC
  4. Venture capital funding specifically for women’s health biotech and pharmaceuticals has undergone a significant transformation since 2023. While the broader "Women's Health" category is often dominate ...
    Breakout Session 26AB
  5. Enacted in 1992, the Prescription Drug User Fee Act (PDUFA) establishes how regulated industry fees support the human drug review program at the Food and Drug Administration (FDA) and associated Agenc ...
    Breakout Session 29AB
9:00 AM (PT)
  1. Novel manufacturing technologies can help rapidly scale manufacturing capabilities, increase supply chain resilience, bring manufacturing closer to the patient, and support greener manufacturing. On a ...
    Breakout Session 23BC
  2. In an increasingly selective capital environment, a handful of biotech CEOs have managed to defy the odds—closing $100 million-plus financing rounds that fueled major growth, platform expansion, and p ...
    Breakout Session 25ABC
  3. The biopharmaceutical industry faces persistent misinformation campaigns targeting patent practices, with myths about patent thickets, evergreening, and excessive patent filings driving misguided poli ...
    Breakout Session 29C
  4. Colorado’s life sciences community is relentlessly focused on patients. In this interactive panel, Colorado BioScience Association President & CEO along with the other panelists, will share real-world ...
    Breakout Session 26AB
10:00 AM (PT)
  1. Company Presentations
    Company Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...
    Company Presentation Session
10:15 AM (PT)
  1. Cell and gene therapies have become invaluable modalities in the medicine toolkit. Following recent safety concerns with AAV vector technology, experts will look increasingly toward new vectors and de ...
    Breakout Session 23BC
  2. Antibody–drug conjugates (ADCs) reshaped cancer treatment by combining the precision of targeted antibodies with the potency of cytotoxic therapies, but as the field matures, the focus is shifting tow ...
    Breakout Session 24BC
  3. The path from academic discovery to patient impact has never been more complex. Federal funding shifts, market turbulence, and evolving expectations for commercialization are challenging traditional m ...
    Breakout Session 29AB

white squarewhite

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS

Loading